Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its price target lowered by analysts at Maxim Group from $8.00 to $5.00. They now have a "buy" rating on the stock.
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences